CellCure Neurosciences

Company Overview

Snapshot

Founded in November 2005, CellCure Neurosciences operates with 11–50 employees. The company has raised $21.79 million across 9 funding rounds from 3 investors. In December 2021, CellCure Neurosciences established an exclusive worldwide collaboration with Genentech for the development and commercialization of its OpRegen® RPE Cell Therapy.

Business overview

CellCure Neurosciences is a biotechnology company focused on developing cell therapies derived from human embryonic stem cells to treat retinal and neural degenerative diseases. The company's core technology involves manufacturing retinal pigment epithelial (RPE) cells from these stem cells. Its primary product in development, OpRegen, utilizes hESC-derived RPE cells for the treatment of age-related macular degeneration (AMD), specifically targeting the dry form of AMD. CellCure Neurosciences operates within the Health Tech & Life Sciences sector, serving the biotechnology and pharmaceutical industries.

Strategic signal

In December 2021, CellCure Neurosciences announced an exclusive worldwide collaboration with Genentech for the development and commercialization of its OpRegen® RPE Cell Therapy. This strategic partnership provides significant validation for CellCure's technology and product pipeline, indicating strong potential for accelerated development and broader market reach for its cell therapies targeting ocular disorders.

Company Intelligence Q&A

What is CellCure Neurosciences' primary focus?

CellCure Neurosciences focuses on developing cell therapies based on human embryonic stem cells for the treatment of retinal and neural degenerative diseases.

What is the status of CellCure Neurosciences' lead product, OpRegen?

OpRegen, CellCure Neurosciences' lead product containing hESC-derived RPE cells for age-related macular degeneration (AMD), is currently undergoing a Phase 1/2 clinical trial to treat dry AMD.

When did CellCure Neurosciences establish a collaboration with Genentech?

In December 2021, CellCure Neurosciences established an exclusive worldwide collaboration with Genentech for the development and commercialization of its OpRegen® RPE Cell Therapy for ocular disorders.

Has CellCure Neurosciences received any grants for its development efforts?

In May 2019, BioTime, CellCure Neurosciences' parent company, was awarded a grant from the Israel Innovation Authority for the continued development of OpRegen®.

Which investors participated in CellCure Neurosciences' October 2010 funding round?

In October 2010, CellCure Neurosciences received funding from BioTime Inc. and Hadasit Bio-Holdings.